SCHEMBL22886458

SCHEMBL22886458

Cn1cc(C2CNC2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.43
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
HSD11B1 P28845 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
SPR P35270 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
USP30 Q70CQ3 1/20 0.34
CHEK1 O14757 6/20 0.33
CCNA2 P20248 5/20 0.33
CDK2 P24941 5/20 0.33
CCNA1 P78396 5/20 0.33
CHRNB2 P17787 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31644282 0.98 HCAR2 (0.42) HCAR2HDAC3HDAC4HDAC7HDAC8
SCHEMBL15219422 0.85 HTR3A (0.44) HCAR2CHEK1CCNA2CDK2CCNA1
SCHEMBL22945192 0.83 CHEK1 (0.48) CHEK1CCNA2CDK2CCNA1IRAK4
SCHEMBL25957974 0.81 HCAR2 (0.37) HCAR2HDAC3HDAC4HDAC7HDAC8
SCHEMBL16131370 0.80
SCHEMBL17940604 0.80 SLC18A3 (0.44) HCAR2HRH3HSD11B1DYRK1ACHEK1
Hydrochloric Acid SCHEMBL2885168 0.79 SLC18A3 (0.42) HCAR2HRH3HSD11B1DYRK1ACHEK1
SCHEMBL25048372 0.77 CREBBP (0.44) HCAR2HDAC3HDAC4HDAC7HDAC8
SCHEMBL25731550 0.77 HSD11B1 (0.44) HCAR2HDAC3HDAC4HDAC7HDAC8
SCHEMBL21733885 0.75 CREBBP (0.45) HCAR2HDAC3HDAC4HDAC7HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215030-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 US disclosed
EP-4499656-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2025-02-05 EP disclosed
CN-119183453-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-12-24 CN disclosed
WO-2023192960-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-10-05 WO disclosed
WO-2023192960-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-10-05 WO disclosed
WO-2021004535-A1 CINNOLINES AS INHIBITORS OF HPK 1 NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) 2021-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215030-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A HCAR2 1791/4885HDAC3 219/4885HDAC4 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.